Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Endocrinology
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
Related Questions
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
Why are patients getting enzalutamide s/p prostatectomy not candidates for salvage radiation therapy?
Does a negative staging PSMA PET in a patient with biopsy-proven recurrent prostatic adenocarcinoma change your management?
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
In what situations would a standard FDG PET/CT be useful in the evaluation of high risk prostate cancer?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
How would you sequence PARPi vs pembrolizumab for a patient who has progressed on ARPI to mCRPC that has somatic PALB2 mutation and MSI-H?
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
